Gsa Capital Partners LLP Glycomimetics Inc Transaction History

Gsa Capital Partners LLP

$1.19 Billion
Q1 2024

A detailed history of Gsa Capital Partners LLP transactions in Glycomimetics Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 18,321 shares of GLYC stock, worth $6,045. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,321

Previous 200,993 90.88%

Holding current value

$6,045

Previous $474,000 88.61%

% of portfolio

0.0%

Previous 0.04%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$2.55 - $3.49 $465,813 - $637,525	-182,672 Reduced 90.88%	18,321 $54,000
Q4 2023 Feb 16, 2024	BUY	$1.13 - $2.54 $121,145 - $272,308	107,208 Added 114.31%	200,993 $474,000
Q3 2023 Nov 15, 2023	BUY	$1.29 - $1.73 $120,982 - $162,248	93,785 New	93,785 $140,000
Q1 2022 May 11, 2022	SELL	$1.0 - $1.58 $146,078 - $230,803	-146,078 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $210,352 - $312,606	146,078 New	146,078 $210,000

Q2 2020 Aug 11, 2020	SELL	$2.06 - $3.76 $49,093 - $89,608	-23,832 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$1.83 - $5.41 $15,355 - $45,395	8,391 Added 54.34%	23,832 $54,000
Q4 2019 Feb 12, 2020	BUY	$4.03 - $6.5 $62,227 - $100,366	15,441 New	15,441 $82,000
Q3 2019 Nov 12, 2019	SELL	$2.8 - $12.85 $43,439 - $199,354	-15,514 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$10.6 - $13.12 $164,448 - $203,543	15,514 New	15,514 $185,000
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $214,140 - $288,960	-21,500 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$8.47 - $14.71 $182,105 - $316,265	21,500 New	21,500 $204,000
Q1 2018 May 11, 2018	SELL	$16.06 - $25.35 $1.39 Million - $2.2 Million	-86,700 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $911,217 - $1.49 Million	86,700	86,700 $1.46 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $17.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Glycomimetics Inc Transaction History